Kyorin And Novartis Enter Into A Global License Agreement For Krp-M223
03/03/2025 07:03
March 3 (Reuters) - Kyorin Pharmaceutical Co Ltd 4569.T: KYORIN PHARMACEUTICAL CO LTD: KYORIN AND NOVARTIS ENTER INTO A GLOBAL LICENSE AGREEMENT FOR KRP-M223 KYORIN PHARMACEUTICAL CO LTD: KYORIN GRANTS NOVARTIS AN EXCLUSIVE WORLDWIDE LICENSE TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE KRP-M223 KYORIN : WILL RECEIVE AN UPFRONT PAYMENT OF USD 55 MILLION AND IS ELIGIBLE TO RECEIVE MILESTONE PAYMENTS OF UP TO USD 777.5 MILLION TIED TO PROGRESS OF DEVELOPMENT, APPROVAL, AND COMMERCIALIZATION OF KRP- M223 Source text: ID:nTSoc8f429 Further company coverage: 4569.T (Reporting by Tokyo Newsroom) ((+81345201189;))